These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 737897)

  • 41. In vitro production of anti-histone antibodies by spleen cells from young autoantibody negative NZB/NZW mice.
    O'Dell JR; Kotzin BL
    J Immunol; 1985 Aug; 135(2):1101-7. PubMed ID: 3874228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin A treated (NZB X NZW) F1 mice.
    Israel-Biet D; Noel LH; Bach MA; Dardenne M; Bach JF
    Clin Exp Immunol; 1983 Nov; 54(2):359-65. PubMed ID: 6360436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice.
    Adam C; Thoua Y; Ronco P; Verroust P; Tovey M; Morel-Maroger L
    Clin Exp Immunol; 1980 May; 40(2):373-82. PubMed ID: 6160000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accelerated deaths from systemic lupus erythematosus in NZB x NZW F1 mice treated with the testosterone-blocking drug flutamide.
    Walker SE; Besch-Williford CL; Keisler DH
    J Lab Clin Med; 1994 Sep; 124(3):401-7. PubMed ID: 8083583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Augmented incidence of neoplasia in NZB-NZW mice treated with long-term cyclophosphamide.
    Walker SE; Bole GG
    J Lab Clin Med; 1973 Oct; 82(4):619-33. PubMed ID: 4755436
    [No Abstract]   [Full Text] [Related]  

  • 46. Analysis of the genetic encoding of oestradiol suppression of delayed-type hypersensitivity in (NZB x NZW) F1 mice.
    Carlsten H; Holmdahl R; Tarkowski A
    Immunology; 1991 Jun; 73(2):186-90. PubMed ID: 2071164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dietary fat and immune function. I. Antibody responses, lymphocyte and accessory cell function in (NZB x NZW)F1 mice.
    Morrow WJ; Ohashi Y; Hall J; Pribnow J; Hirose S; Shirai T; Levy JA
    J Immunol; 1985 Dec; 135(6):3857-63. PubMed ID: 2415589
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Resistance to therapy in mature Palmerston North mice treated with cyclophosphamide or hydrocortisone sodium succinate.
    Walker SE; Schnitzer B
    Arthritis Rheum; 1980 May; 23(5):539-44. PubMed ID: 6966498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclophosphamide protection in NZB/NZW disease. Mechanisms and therapeutic regimens.
    Morris AD; Esterly J; Chase G; Sharp GC
    Arthritis Rheum; 1976; 19(1):49-55. PubMed ID: 130137
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accelerated mortality in young NZB/NZW mice treated with the interferon inducer tilorone hydrochloride.
    Walker SE
    Clin Immunol Immunopathol; 1977 Sep; 8(2):204-12. PubMed ID: 902437
    [No Abstract]   [Full Text] [Related]  

  • 51. [Tilorone, a synthetic immunostimulator possessing antitumor activity].
    Kavetskiĭ RE; Balitskiĭ KP; Veksler IG; Vetrova EP; Vorontsova AL
    Vopr Onkol; 1977; 23(11):88-93. PubMed ID: 413265
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Late treatment of murine lupus erythematosus with dactinomycin (actinomycin D). I. Course and longevity.
    Gabrielsen AE; Olsen CT
    Clin Exp Immunol; 1979 Jan; 35(1):33-5. PubMed ID: 428145
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of antiviral properties in mice of bis-pyrrolidinoacetamido-fluorenone (MLU-B75), bis-dipropylaminoacetamido-fluorenone (MLU-B76), and tilorone hydrochloride.
    Veckenstedt A; Witkowski W; Hoffmann S
    Acta Virol; 1979 Mar; 23(2):153-8. PubMed ID: 39439
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease.
    Engleman EG; Sonnenfeld G; Dauphinee M; Greenspan JS; Talal N; McDevitt HO; Merigan TC
    Arthritis Rheum; 1981 Nov; 24(11):1396-1402. PubMed ID: 6172132
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tilorone-mediated protection against murine B16 melanoma.
    Turner EV; Wallace JH
    Proc Soc Exp Biol Med; 1981 Sep; 167(4):536-41. PubMed ID: 7279931
    [No Abstract]   [Full Text] [Related]  

  • 56. Therapeutic studies in NZB/W mice. IV. Effect of combination drug therapy on immune complex deposition.
    Gelfand MC; Schur PH; Asofsky R; Steinberg AD
    Arthritis Rheum; 1976; 19(1):43-8. PubMed ID: 130136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Experimental encephalitis caused by herpes simplex virus: comparison of treatment with tilorone hydrochloride and phosphonoacetic acid.
    Fitzwilliam JF; Griffith JF
    J Infect Dis; 1976 Jun; 133 Suppl():A221-5. PubMed ID: 180204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic suppression of the hyperacute form of experimental allergic encephalomyelitis by tilorone and cycloleucine.
    Levine S; Sowinski R
    Proc Soc Exp Biol Med; 1977 Dec; 156(3):457-60. PubMed ID: 594075
    [No Abstract]   [Full Text] [Related]  

  • 59. Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy.
    Steinberg AD; Gelfand MC; Hardin JA; Lowenthal DT
    Arthritis Rheum; 1975; 18(1):9-14. PubMed ID: 1115749
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prolonged lifespans in female NZB/NZW mice treated with the experimental immunoregulatory drug frentizole.
    Walker SE; Solsky M; Schnitzer B
    Arthritis Rheum; 1982 Nov; 25(11):1291-7. PubMed ID: 6982717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.